Adaptin Bio, Inc., a Lucius Partners Portfolio Company, Completes Alternative Public Offering (APO) and Closes $7.7 Million Private Placement
Funding expected to support first clinical trial of APTN-101 for the treatment of glioblastoma CHARLOTTE, N.C., April 07, 2025 (GLOBE NEWSWIRE) ...
Winnipeg Free Press14m
Mennonite newspaper warns of measles danger
Dueck went on to note measles can be deadly for people with compromised immune systems, such as cancer patients, that taking ...
Weekly Commentary: Worse Than The Worst Case
The unfolding global trade war backdrop is uncharted waters. Scenario analysis should now include the possibility of things ...